Do analysts prefer MRKR or TELO?

Marker Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 566.67%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is IBIO or MRKR more profitable?

iBio has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. iBio's return on equity of -53.86% beat Marker Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% Marker Therapeutics -343.03% -56.96% -47.82%

Does the media refer more to IBIO or MRKR?

In the previous week, Marker Therapeutics had 19 more articles in the media than iBio. MarketBeat recorded 21 mentions for Marker Therapeutics and 2 mentions for iBio. Marker Therapeutics' average media sentiment score of 0.31 beat iBio's score of -0.45 indicating that Marker Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Marker Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MRKR or CRDF?

In the previous week, Marker Therapeutics had 12 more articles in the media than Cardiff Oncology. MarketBeat recorded 21 mentions for Marker Therapeutics and 9 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.82 beat Marker Therapeutics' score of 0.31 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marker Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiff Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MRKR or PLRX?

In the previous week, Marker Therapeutics had 17 more articles in the media than Pliant Therapeutics. MarketBeat recorded 21 mentions for Marker Therapeutics and 4 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.65 beat Marker Therapeutics' score of 0.31 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marker Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pliant Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Marker Therapeutics (MRKR) Competitors

$1.50 +0.11 (+7.91%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$1.46 -0.04 (-3.00%)

As of 08/24/2026 05:57 PM Eastern

Compare

MRKR vs. ATRA, TELO, IBIO, CRDF, and PLRX

Should you buy Marker Therapeutics stock or one of its competitors? Marker Therapeutics's main competitors and comparable companies include Atara Biotherapeutics (ATRA), Telomir Pharmaceuticals (TELO), iBio (IBIO), Cardiff Oncology (CRDF), and Pliant Therapeutics (PLRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Marker Therapeutics compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Atara Biotherapeutics currently has a consensus target price of $9.50, indicating a potential upside of 0.42%. Marker Therapeutics has a consensus target price of $10.00, indicating a potential upside of 566.67%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Atara Biotherapeutics has a net margin of -269.42% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -56.96% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%
Marker Therapeutics	-343.03%	-56.96%	-47.82%

Atara Biotherapeutics has a beta of 0.12, suggesting that its share price is 88% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market.

In the previous week, Marker Therapeutics had 21 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 21 mentions for Marker Therapeutics and 0 mentions for Atara Biotherapeutics. Marker Therapeutics' average media sentiment score of 0.31 beat Atara Biotherapeutics' score of 0.00 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Atara Biotherapeutics	Neutral
Marker Therapeutics	Neutral

Atara Biotherapeutics has higher revenue and earnings than Marker Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.79	$32.69M	-$1.18	N/A
Marker Therapeutics	$3.55M	7.04	-$12.16M	-$0.41	N/A

Summary

Marker Therapeutics beats Atara Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Marker Therapeutics compare to Telomir Pharmaceuticals?

Marker Therapeutics (NASDAQ:MRKR) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Marker Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the broader market.

Telomir Pharmaceuticals has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -56.96% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-56.96%	-47.82%
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%

In the previous week, Marker Therapeutics had 21 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 21 mentions for Marker Therapeutics and 0 mentions for Telomir Pharmaceuticals. Marker Therapeutics' average media sentiment score of 0.31 beat Telomir Pharmaceuticals' score of 0.00 indicating that Marker Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Marker Therapeutics	Neutral
Telomir Pharmaceuticals	Neutral

Telomir Pharmaceuticals has lower revenue, but higher earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	7.04	-$12.16M	-$0.41	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A

Marker Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 566.67%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

22.4% of Marker Therapeutics shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Marker Therapeutics beats Telomir Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Marker Therapeutics compare to iBio?

iBio (NASDAQ:IBIO) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

iBio currently has a consensus target price of $5.00, indicating a potential upside of 252.11%. Marker Therapeutics has a consensus target price of $10.00, indicating a potential upside of 566.67%. Given Marker Therapeutics' higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

7.9% of iBio shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 2.8% of iBio shares are owned by insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

iBio has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. iBio's return on equity of -53.86% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
Marker Therapeutics	-343.03%	-56.96%	-47.82%

In the previous week, Marker Therapeutics had 19 more articles in the media than iBio. MarketBeat recorded 21 mentions for Marker Therapeutics and 2 mentions for iBio. Marker Therapeutics' average media sentiment score of 0.31 beat iBio's score of -0.45 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Marker Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

iBio has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

Marker Therapeutics has higher revenue and earnings than iBio. Marker Therapeutics is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	176.36	-$18.38M	-$0.58	N/A
Marker Therapeutics	$3.55M	7.04	-$12.16M	-$0.41	N/A

Summary

Marker Therapeutics beats iBio on 9 of the 17 factors compared between the two stocks.

How does Marker Therapeutics compare to Cardiff Oncology?

Marker Therapeutics (NASDAQ:MRKR) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

In the previous week, Marker Therapeutics had 12 more articles in the media than Cardiff Oncology. MarketBeat recorded 21 mentions for Marker Therapeutics and 9 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.82 beat Marker Therapeutics' score of 0.31 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marker Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiff Oncology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Marker Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 566.67%. Cardiff Oncology has a consensus price target of $7.50, suggesting a potential upside of 651.50%. Given Cardiff Oncology's higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than Marker Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Marker Therapeutics has higher revenue and earnings than Cardiff Oncology. Marker Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	7.04	-$12.16M	-$0.41	N/A
Cardiff Oncology	$590K	131.58	-$45.85M	-$0.60	N/A

Marker Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market.

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Marker Therapeutics has a net margin of -343.03% compared to Cardiff Oncology's net margin of -7,885.43%. Marker Therapeutics' return on equity of -56.96% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-56.96%	-47.82%
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%

Summary

Marker Therapeutics beats Cardiff Oncology on 9 of the 14 factors compared between the two stocks.

How does Marker Therapeutics compare to Pliant Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Marker Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

In the previous week, Marker Therapeutics had 17 more articles in the media than Pliant Therapeutics. MarketBeat recorded 21 mentions for Marker Therapeutics and 4 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.65 beat Marker Therapeutics' score of 0.31 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marker Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pliant Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pliant Therapeutics has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Pliant Therapeutics' return on equity of -52.17% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-56.96%	-47.82%
Pliant Therapeutics	N/A	-52.17%	-40.46%

Marker Therapeutics has higher revenue and earnings than Pliant Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	7.04	-$12.16M	-$0.41	N/A
Pliant Therapeutics	$1.58M	44.68	-$149.34M	-$1.49	N/A

Marker Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 566.67%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 163.16%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Marker Therapeutics is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Marker Therapeutics and Pliant Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Marker Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRKR vs. The Competition

Export

Metric	Marker Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$23.18M	$4.01B	$7.36B	$12.81B
Dividend Yield	N/A	3.64%	2.53%	10.78%
P/E Ratio	-3.66	11.69	270.56	24.05
Price / Sales	7.04	1,415.27	639.67	105.69
Price / Cash	N/A	44.94	29.03	36.89
Price / Book	1.49	17.26	11.18	6.40
Net Income	-$12.16M	-$22.72M	$3.46B	$347.95M
7 Day Performance	30.43%	2.51%	1.73%	1.49%
1 Month Performance	22.95%	9.80%	7.34%	5.15%
1 Year Performance	19.05%	57.43%	26.12%	17.01%

Marker Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRKR Marker Therapeutics	2.4539 of 5 stars	$1.50 +7.9%	$10.00 +566.7%	+16.3%	$23.18M	$3.55M	N/A	60	News Coverage Analyst Revision Gap Up High Trading Volume
ATRA Atara Biotherapeutics	0.9316 of 5 stars	$8.61 +3.0%	$9.50 +10.3%	-23.3%	$77.58M	$120.77M	N/A	330
TELO Telomir Pharmaceuticals	0.4078 of 5 stars	$1.08 +1.4%	N/A	-19.3%	$73.93M	N/A	N/A	1
IBIO iBio	2.709 of 5 stars	$1.43 -1.7%	$5.00 +250.9%	N/A	$71.29M	$400K	N/A	100	Analyst Downgrade
CRDF Cardiff Oncology	3.4226 of 5 stars	$0.92 +1.2%	$7.50 +719.7%	-57.0%	$71.18M	$508K	N/A	20	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRKR) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marker Therapeutics (MRKR) Competitors

MRKR vs. ATRA, TELO, IBIO, CRDF, and PLRX

How does Marker Therapeutics compare to Atara Biotherapeutics?

Summary

How does Marker Therapeutics compare to Telomir Pharmaceuticals?

Summary

How does Marker Therapeutics compare to iBio?

Summary

How does Marker Therapeutics compare to Cardiff Oncology?

Summary

How does Marker Therapeutics compare to Pliant Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marker Therapeutics (MRKR) Competitors

MRKR vs. ATRA, TELO, IBIO, CRDF, and PLRX

How does Marker Therapeutics compare to Atara Biotherapeutics?

Do analysts prefer ATRA or MRKR?

Do insiders and institutionals believe in ATRA or MRKR?

Is ATRA or MRKR more profitable?

Which has more volatility and risk, ATRA or MRKR?

Does the media refer more to ATRA or MRKR?

Which has higher earnings & valuation, ATRA or MRKR?

Summary

How does Marker Therapeutics compare to Telomir Pharmaceuticals?

Which has more volatility & risk, MRKR or TELO?

Is MRKR or TELO more profitable?

Does the media favor MRKR or TELO?

Which has better earnings and valuation, MRKR or TELO?

Do analysts prefer MRKR or TELO?

Do institutionals & insiders believe in MRKR or TELO?

Summary

How does Marker Therapeutics compare to iBio?

Do analysts recommend IBIO or MRKR?

Do insiders & institutionals have more ownership in IBIO or MRKR?

Is IBIO or MRKR more profitable?

Does the media refer more to IBIO or MRKR?

Which has more risk & volatility, IBIO or MRKR?

Which has preferable valuation & earnings, IBIO or MRKR?

Summary

How does Marker Therapeutics compare to Cardiff Oncology?

Does the media prefer MRKR or CRDF?

Do analysts prefer MRKR or CRDF?

Which has better valuation & earnings, MRKR or CRDF?

Which has more volatility and risk, MRKR or CRDF?

Do insiders and institutionals have more ownership in MRKR or CRDF?

Is MRKR or CRDF more profitable?

Summary

How does Marker Therapeutics compare to Pliant Therapeutics?

Which has more risk and volatility, MRKR or PLRX?

Does the media prefer MRKR or PLRX?

Is MRKR or PLRX more profitable?

Which has preferable valuation and earnings, MRKR or PLRX?

Do analysts rate MRKR or PLRX?

Do institutionals and insiders have more ownership in MRKR or PLRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools